GlassScriptPhysician profile
Shaun E Laurie
NPI 1952344285
$7,200.76
in general payments reported to CMS, 2019-2025
46 companies · $412 in 2025
The $412 reported for 2025 was more than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $875 · 2020: $1,314 · 2021: $1,822 · 2022: $1,180 · 2023: $893 · 2024: $706 · 2025: $412.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,946 · Education: $64.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,945.97 |
| Education | $64.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,076.78 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Astellas Pharma US INC | $727.11 | 2019-2025 | Veozah, Myrbetriq |
| Pfizer INC. | $484.29 | 2019-2025 | |
| Lilly USA, LLC | $423.70 | 2020-2025 | Mounjaro, Amyvid, Kisunla |
| Novartis Pharmaceuticals Corporation | $381.14 | 2019-2023 | |
| Astrazeneca Pharmaceuticals LP | $332.63 | 2019-2025 | Airsupra, Breztri |
| Boehringer Ingelheim Pharmaceuticals, INC. | $317.58 | 2019-2024 | Jardiance |
| Abbvie INC. | $267.07 | 2019-2022 | |
| Sunovion Pharmaceuticals INC. | $242.54 | 2019-2022 | |
| Avanir Pharmaceuticals, INC. | $207.68 | 2020-2022 | |
| Nestle Healthcare Nutrition INC. | $196.99 | 2020-2022 | |
| Abbott Laboratories | $194.05 | 2019-2025 | Freestyle Libre 3 |
| Kowa Pharmaceuticals America, INC. | $176.77 | 2020-2023 | Livalo |
| E.R. Squibb & Sons, L.L.C. | $162.07 | 2019-2025 | Eliquis, Camzyos |
| Bayer Healthcare Pharmaceuticals INC. | $152.56 | 2021-2024 |
Show all 46 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $139.20 | 2019-2023 | Trelegy Ellipta |
| Eisai INC. | $131.28 | 2020-2024 | |
| Merck Sharp & Dohme LLC | $125.01 | 2020-2021 | |
| Global Blood Therapeutics, INC. | $121.06 | 2020-2022 | |
| Biogen, INC. | $119.10 | 2021 | |
| Janssen Pharmaceuticals, INC | $109.38 | 2019-2022 | |
| Jazz Pharmaceuticals INC. | $94.72 | 2021-2023 | Epidiolex |
| Phathom Pharmaceuticals, INC. | $83.08 | 2024-2025 | Voquezna |
| Neurocrine Biosciences, INC. | $80.15 | 2022-2024 | Ingrezza, Ongentys |
| Otsuka America Pharmaceutical, INC. | $71.48 | 2022-2023 | Nuedexta, Rexulti |
| Ucb, INC. | $69.88 | 2021-2025 | Nayzilam |
| Xeris Pharmaceuticals, INC. | $67.95 | 2021-2022 | |
| Dexcom, INC. | $66.99 | 2021-2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $61.04 | 2023-2024 | Rexulti |
| Neurelis, INC. | $58.61 | 2022-2024 | Valtoco |
| Aimmune Therapeutics, INC. | $46.50 | 2024-2025 | Zenpep |
| Amarin Pharma, INC. | $44.35 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $39.18 | 2023 | Austedo |
| Allergan, INC. | $37.96 | 2020 | |
| Corcept Therapeutics | $36.83 | 2023 | Korlym |
| Amgen INC. | $33.31 | 2022-2025 | Repatha, Otezla |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.45 | 2019 | |
| Organogenesis INC. | $28.06 | 2025 | Apligraf |
| Urovant Sciences INC | $24.34 | 2021 | |
| Medtronic, INC. | $23.73 | 2025 | Inceptiv |
| Daiichi Sankyo INC. | $23.43 | 2021 | |
| Sanofi-Aventis U.S. LLC | $20.81 | 2019 | |
| Circassia INC. | $19.97 | 2019 | |
| Emmaus Medical, INC. | $19.40 | 2022-2023 | Endari |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.82 | 2025 | Caplyta |
| Sanofi Pasteur INC. | $11.73 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Shaun Laurie listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.